A new heart drug appears to help people with a rare stiff heart condition stay more stable than the older standard treatment. In early real-world use, patients starting acoramidis needed fewer increases in diuretics and had fewer hospitalizations compared with those taking tafamidis.
This matters because transthyretin amyloid cardiomyopathy (ATTR-CM) is a serious disease. It happens when a protein called transthyretin builds up in the heart muscle. Over time, the heart becomes stiff and struggles to pump. Fluid can back up, causing swelling and shortness of breath. Many patients end up needing stronger diuretics, going to the hospital for heart failure, or facing a shorter lifespan.
Until recently, tafamidis was the only approved therapy in the United States. It works by stabilizing the transthyretin protein so it doesn’t fall apart and form deposits. Acoramidis, approved in 2024, also stabilizes this protein, but it aims for near-complete stabilization—meaning it keeps more than 90% of the protein intact. Until now, doctors haven’t had head-to-head trials to compare them directly.
But here’s the twist: researchers turned to real-world data to see how these two drugs perform outside of a controlled trial. This approach can reveal how treatments work in everyday practice, where patients are older, have more health conditions, and take multiple medications.
Think of the transthyretin protein like a factory that makes a product. In ATTR-CM, the factory’s parts start to break down, and the broken pieces pile up and clog the heart’s machinery. Tafamidis acts like a clamp that holds the factory parts together. Acoramidis may act like a stronger clamp, keeping more parts intact so fewer broken pieces escape. By stabilizing more of the protein, acoramidis could reduce the debris that stiffens the heart and triggers fluid buildup.
The study used a large U.S. claims database, which tracks insurance claims to see what treatments people receive and what happens to their health. Researchers looked at people who newly started either acoramidis or tafamidis between December 2024 and April 2025. They followed them for up to several months, until mid-2025. To make the groups as similar as possible, they used statistical weighting to balance age, sex, disease severity, other health conditions, and baseline medications. The acoramidis group included 170 patients, while the tafamidis group had a weighted sample of 448 patients. The average age was about 79 years, and most were male. Follow-up averaged about 140 days.
The researchers focused on two key outcomes. First, diuretic intensification—starting a diuretic, increasing the dose, or adding another type of diuretic. Second, a combined outcome that included diuretic intensification, heart failure hospitalizations, and death. These are practical, patient-centered events that reflect how stable someone’s condition is over time.
Acoramidis showed a clear advantage. About 12% of acoramidis patients needed diuretic intensification, compared with 21% on tafamidis. That’s a 43% lower risk over the study period. For the combined outcome, 18% of acoramidis patients had an event, versus 26% on tafamidis—a 34% lower risk. Both differences were statistically significant, meaning they’re unlikely to be due to chance.
But there’s a catch. This study only followed patients for about four to five months. That’s enough to see early signals, but not long enough to know how these drugs affect survival or major heart events over years. It’s also an observational study, not a randomized trial, so even with careful weighting, there could be hidden differences between the groups.
Still, the pattern fits with what we know about how these drugs work. Acoramidis aims for near-complete stabilization of the transthyretin protein, which may translate into better clinical stability in the real world. Experts note that real-world evidence like this can complement randomized trials, especially when head-to-head data are scarce. It helps doctors and patients make informed choices while longer-term studies are underway.
This doesn’t mean acoramidis is the right choice for everyone.
If you or a loved one has ATTR-CM, talk with your cardiologist about which therapy may be best. Consider your overall health, other medications, and how closely you can be monitored. Acoramidis is available, but insurance coverage and access may vary. Tafamidis remains a proven option, and some patients may do well on it.
The study has important limitations. It was short, used a relatively small sample, and relied on insurance claims rather than detailed clinical exams. Claims data can miss some events or misclassify diagnoses. The findings need confirmation in larger, longer studies, ideally with prospective follow-up and clinical endpoints like heart function tests and quality of life.
What happens next? Researchers are likely to continue comparing these drugs in larger real-world cohorts and in planned or ongoing clinical studies. Longer follow-up will help clarify whether the early stability seen with acoramidis translates into fewer hospitalizations over time and, ultimately, better survival. For now, this early real-world evidence suggests acoramidis may offer a meaningful step forward in keeping people with ATTR-CM more stable, but more data are on the way.
